fbpx

Year

2017
Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing Ness Ziona, Israel and Chapel Hill, NC – December 4, 2017 – Atox Bio, a clinical stage biotechnology company developing novel therapies for critically ill patients, today announced that...
Lund, Sweden, 18:00 CET 30 November 2017 – During November, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 30 November 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 50,000,821. For more information contact: Richard Davies, CEO...
BURLINGTON, Mass., November 29, 2017 (GLOBE NEWSWIRE) – scPharmaceuticals Inc. (the “Company” or “scPharmaceuticals”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced it has issued an additional 894,968 shares of common stock at the...
BURLINGTON, Mass., Nov. 29, 2017 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (the “Company”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced the closing of its initial public offering of 6,400,000 shares of common stock at a public...
The Lundbeck Foundation has appointed Thomas Sinkjær as Senior Vice President of Grants & Prizes as of 1 January 2018. This is a new post aimed at strengthening and focusing the Foundation’s grant allocation activities, which include its prestigious brain research accolade, The Brain Prize. The Lundbeck Foundation grants almost half a billion Danish kroner...
Lund, Sweden, 18.30 CET, 22 November 2017 – BONESUPPORT HOLDING AB (publ), an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that the Nomination Committee for the Annual General Meeting 2018 has been appointed. According to...
Lund, Sweden, 08.00 CET, 20 November 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces it has signed a second distribution agreement for Italy with Citieffe Srl to strengthen its access to trauma...
BURLINGTON, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (the “Company”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced the pricing of its initial public offering of 6,400,000 shares of common stock at a public...
Lund, Sweden, 08.00 CET, 14 November 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, announces the publication of a paper highlighting the anti-biofilm activity of CERAMENT® G in vitro – Colloids and Surfaces B:...
Cancer biologist and professor Janine Erler, of the University of Copenhagen, receives The Lundbeck Foundation’s Research Prize for Young Scientists. She has delivered one landmark research outcome after another in the field of cancer and, as a result, she has become an internationally recognised top scientist with publications in the most significant scientific journals. For...
1 2 3 4 9

News

Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge